At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Prostaglandin D antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
Most Recent Events
- 03 Jun 1997 No-Development-Reported for Ischaemic heart disorders in United Kingdom (Unknown route)